Eric K. Rowinsky, M.D.
Chairman
Eric K. Rowinsky, M.D., has decades of experience in corporate strategy, academia, research and drug development in the oncology space. He has been the Executive Director and President of RGenix, Inc. since June 2016. He also has served as the Chief Scientific Officer of Clearpath Development Co. since June 2016. Prior to this, Dr. Rowinsky served as the Head of Research and Development, Chief Medical Officer and Executive Vice President of Stemline Therapeutics, Inc. from February 2011 to January 2016. In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer, until it was acquired in 2011. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly and Company. Previous to that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Fortress Biosciences, Inc., and Verastem Inc. He formerly served on the boards of directors of the public companies Navidea Biopharmaceuticals Inc. (2010-2018), BIND Therapeutics (2014-2016), and Biophytis S.A. (2018-2019) as well as at a number of privately held companies. Dr. Rowinsky received a B.A. degree in Liberal Arts from New York University. He earned his M.D. from Vanderbilt University School of Medicine and completed a residency in internal medicine at University of California and a fellowship in medical oncology at Johns Hopkins University. Dr. Rowinsky led the clinical development and regulatory approval of several oncology therapies, including Erbitux (cetuximab).
Isaac Israel
Isaac Israel has served as Kitov's CEO and a member of the board since 2012. Mr. Israel was the founding CEO of BeeContact (formerly TASE: BCNT), from 2001 until 2007. Since 2008, Mr. Israel has served as owner and founding CEO of Uneri Capital, a consulting firm in the capital markets field that specializes in the healthcare sector. Mr. Israel also serves as a member of the board of directors of various public and private healthcare corporations, including chairman of the board of NextGen Biomed, which is traded on the TASE.Simcha Rock – CPA, MBA
Simcha Rock has served as a member of the board since 2013. He was Kitov’s CFO from 2013 through the end of 2018 when he retired from the position. Mr. Rock was a Private Equity Manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from 2000 until 2011. In that capacity, he was responsible for all financial, legal and administrative matters for several investment funds. Prior to that, Mr. Rock held financial management positions at Intel Electronics, The Jerusalem College of Technology, and JC Technologies. Mr. Rock holds a BA from Yeshiva University and an MBA from Cleveland State University.
Ido Agmon - MBA
Ido Agmon has served as a member of Kitov’s board since 2016. Mr. Agmon is a Manager of Aviv New-Tech, a private investment fund that manages a portfolio of public Israeli and global biomed and technology companies. He also serves as an independent consultant, providing startups and technology-based ventures with strategic planning and fundraising advice. Previously, he served as the CEO of Meytav Technology Incubator, an Israeli-based accelerator for biotech, pharma and medtech ventures with over 20 portfolio companies. Mr. Agmon has also served as a board member for a number of biomed ventures. He was the Director of Business Development at the ATI incubator, a technology incubator specializing in biomed and cleantech projects, where he was responsible for deal-flow and project evaluation. Mr. Agmon holds a BA in Business Administration and Life Sciences from Tel Aviv University, and an MBA from The Hebrew University of Jerusalem.Steven Steinberg - CPA
Steven Steinberg has served as a member of Kitov’s board since 2016. Mr. Steinberg is the Chief Financial Officer of Glide Talk, a technology company in the video messaging arena. He previously served as Vice President, Finance at ClientConnect, a subsidiary of Conduit. Mr. Steinberg has provided startups and mature organizations with advice in financial reporting, due diligence and business models. He also served as CFO of Answers Corporation, a NASDAQ-listed company. He has held a number of finance and CFO roles following a 10-year stint as an Audit Manager at Coopers & Lybrand (currently Price Waterhouse Coopers) in New York City. Mr. Steinberg holds a BA in Business Administration from Florida International University – School of Business Administration, and was granted a CPA license in New York State.Arye Weber - MA
Arye Weber has served as a member of Kitov’s board since 2017. Since 2001, Mr. Weber has been the chairman of the board and sole shareholder of Scorpio Investments, a private holding company for various investments. Between 2006 and 2009, Mr. Weber was the CEO of Alonei Meitar, a TASE-listed real estate development company. Between 2004 and 2008, Mr. Weber was the chairman of the board of Inventec Investments, a TASE-listed real estate development company. Between 1989 and 2002, Mr. Weber was the Manager of the Securities & Investments sector at United Mizrachi Bank, and prior to 1989, he served in various securities and investments department roles at the bank. Mr. Weber serves as a member of the board of directors of various public and private corporations. In the past, he held director positions at the Tel Aviv Stock Exchange Clearing House (chairman), Bank Mizrachi Registration Company (chairman), Mashabim United Mizrachi Bank Offerings Company, Tel Aviv Stock Exchange, Maalot Israel Rating Agency, and Excellence Investment Management Company. Mr. Weber holds an MA in Economics and Business Studies from the University of Kharkov, USSR (presently Ukraine).